Multi-Omics Personalized Medicine

FORTIS & PEAK PERSPECTIVES | APPLIED FORESIGHT

Multi-Omics Personalized Medicine has transitioned from an aspirational research field into a standardized clinical infrastructure. While 2024 was about "reading the code" through Genomics, **2026 is about "observing the function"** – integrating the entire biological stack and moving from Population-Based Health to Individual Molecular Orchestration.

This perspective expands on the three layers of hyper-precision transformation that Fortis & Peak believes will define the next era of clinical practice and strategic health investment.

Fortis & Peak
Shaping What's Next

The Multi-Omics Stack: Beyond the Genome

In 2026, a "full workup" for high-risk patients integrates four distinct data layers to create a **"Live GPS" of health.** Each layer captures a different dimension of biological reality – from inherited blueprint to real-time cellular response – enabling a level of diagnostic precision that was impossible just two years ago.

Genomics – The Blueprint

Identifies inherited risks such as BRCA1/2 using NovaSeq X Plus sequencers. The cost of a whole-genome sequence has dropped to nearly **$100**, making population-scale screening viable.

Proteomics – The Machinery

Monitors proteins currently active in the body. Since proteins change in response to disease long before symptoms appear, this enables **"Early-Stage Signal"** detection in oncology and neurology.

Metabolomics – The Exhaust

Analyzes small-molecule metabolites produced by cellular processes, providing a real-time **"Snapshot"** of how a patient is processing energy and responding to environmental stressors.

Transcriptomics – The Instruction

Measures RNA to reveal which genes are "turned on" or "off" at any given moment, allowing physicians to observe the body's **immediate response** to a specific therapy in real time.

Pharmacogenomics (PGx) as a Prescribing Mandate

As of **January 1, 2026**, updated clinical guidelines from Carelon and the NHS have elevated PGx testing to a **"Medical Necessity"** for dozens of high-volume drugs. This represents a fundamental shift in how physicians approach prescribing – eliminating the costly and dangerous trial-and-error model that has defined pharmacotherapy for decades.

The "Zero-Trial" Prescribing Model

Doctors no longer use trial-and-error for medications like Clopidogrel (Plavix) or Warfarin. A patient's CYP2C19 or CYP2C9 genotype is checked before the first dose to confirm they are not a "Poor Metabolizer," preventing thousands of Adverse Drug Reactions (ADRs) annually.

Standardized Reporting

The GA4GH (Global Alliance for Genomics and Health) has finalized the **2026 PGx Data Standard**, enabling a patient's genetic "metabolic profile" to follow them across different hospital systems and even international borders – a critical step toward truly portable precision medicine.

Measured Impact

This standardization has resulted in a **75% reduction in avoidable side effects** for patients on multi-drug regimens, significantly lowering the Total Cost of Care for chronic disease management.

CRISPR & Gene Therapies: The Cure as a Service

2026 marks the **"Scaling Phase"** for gene editing. Therapies that were revolutionary "firsts" in 2024 – such as Casgevy for Sickle Cell Disease – are now part of a mature, regulated reality. The field has moved decisively from proof-of-concept to clinical deployment at scale.

1 One-Time Cures via FDA's "Plausible Mechanism" Pathway

The FDA's new pathway (February 2026) has accelerated approvals for rare disease gene therapies. The paradigm is shifting from **"managing" symptoms to "editing" the underlying genetic error** – a fundamental redefinition of what medicine can achieve.

2 In-Vivo Editing Breakthroughs

While early CRISPR therapies required complex ex-vivo cell modification, 2026 is seeing the **first wave of In-Vivo (inside the body) editing trials.** This simplifies treatment and could make curative therapies accessible beyond elite specialized centers.

3 The "Value-Based" Price Model

To address multi-million-dollar cure costs, Fortis & Peak advises clients on **"Annuity-Based Reimbursement"** – where the payer compensates the manufacturer over 10 years, contingent on the patient remaining cured. This aligns financial incentives with clinical outcomes.

The Fortis & Peak "Precision Health" ROI

Across the full clinical pathway – from initial screening to long-term monitoring – the multi-omics framework delivers measurable, compounding returns. The table below maps each phase to its 2026 methodology and the peak benefit Fortis & Peak clients can expect to realize.

Phase	Methodology	2026 "Peak" Benefit
Diagnostics	Multi-Omic Screening	Detection 12-18 months earlier than imaging
Prescribing	Standardized PGx	90% reduction in "High-Risk" ADRs
Treatment	CRISPR / Gene Therapy	One-time curative cost vs. lifelong care
Monitoring	Liquid Biopsy (ctDNA)	Real-time adjustment of oncology protocols

$100

Whole-Genome Sequencing

Cost per sequence with NovaSeq X Plus, down from thousands just years ago.

75%

Reduction in ADRs

Avoidable side effects eliminated for patients on multi-drug regimens via PGx.

18mo

Earlier Detection

Multi-omic screening detects disease 12-18 months ahead of traditional imaging.

90%

High-Risk ADR Reduction

Achieved through standardized PGx prescribing mandates across health systems.

Strategic Recommendation: AI Clinical Co-Pilots

The 2026 bottleneck is **"Clinical Interpretability."** Most primary care physicians are overwhelmed by multi-omic data. The volume, complexity, and novelty of integrated genomic, proteomic, metabolomic, and transcriptomic outputs exceed what any individual clinician can synthesize in a standard consultation window – creating a dangerous gap between data availability and actionable insight.

Fortis & Peak leads by implementing **"AI Clinical Co-Pilots."** We help health systems deploy the **"translation layer"** that converts complex raw omic data into a simple, actionable **"Prescribing Scorecard"** for the physician. This ensures that Hyper-Precision does not lead to Clinical Paralysis – the single greatest implementation risk facing health systems today.

Raw Omic Data

Genomic, proteomic, metabolomic, and transcriptomic outputs from multi-layer patient workups.

AI Translation Layer

Fortis & Peak-deployed co-pilot systems that synthesize and contextualize complex biological signals.

Prescribing Scorecard

A simple, actionable clinical output that empowers physicians to act with confidence and precision.

About Fortis & Peak Perspectives

> Fortis & Peak Perspectives represent our forward-looking view on the forces shaping industries, business models, and competitive advantage.

Drawing on deep strategic insight and cross-sector experience, these perspectives go beyond observation to frame what matters most – and what comes next. They are designed to help executives interpret disruption, anticipate shifts, and make informed decisions with clarity and confidence in an increasingly complex business environment.

Applied Foresight

We translate emerging signals into strategic clarity, helping clients stay ahead of disruption rather than react to it.

Cross-Sector Intelligence

Our perspectives draw on patterns across industries, surfacing insights that sector-specific analysis routinely misses.

Executive Decision Support

Every perspective is designed to be actionable – equipping leaders to make informed, confident decisions under uncertainty.

www.fortisandpeak.com | info@fortisandpeak.com

Fortis & Peak
Shaping What's Next